GeneGo has licensed MetaCore, its data mining and analysis platform, to Proteostasis Therapeutics (Proteostasis).
Julie Bryant, VP of business development at GeneGo, said: We are very pleased to add Proteostasis as a new customer as we work towards delivering our disease specific platforms. Understanding and capturing disease pathways is one of our top development priorities, and we are glad to see it appreciated by drug discovery companies.
Hui Ge, head of systems biology at Proteostasis, said: Proteostasis Therapeutics is building a proprietary platform to rapidly translate the emerging knowledge of how the Proteostasis Network functions to discover novel small molecules, and GeneGo’s MetaCore integrated software suite is a valuable tool in these efforts. We are pleased with GeneGo’s comprehensive curated database of protein interactions, which enables us to rapidly use this information in our Proteostasis Network characterization efforts.